SONN
Sonnet BioTherapeutics Holdings Inc
Halal Rating :
Last Price
$1.53
Last updated:
Market Cap
-
7D Change
-3.16%
1 Year Change
15.91%
Company Overview
Industries
Exchange
Next Earnings Date
Sonnet BioTherapeutics Holdings Inc is a clinical-stage biopharmaceutical company developing innovative targeted biologic drugs. The company focuses on developing novel therapeutic candidates for treating cancer and autoimmune diseases using its proprietary FHAB (Fully Human Albumin Binding) technology platform.
The company is currently in development and research phase, with multiple candidates in its pipeline including SON-1010, SON-080, and SON-1210, which are being evaluated for various oncology and autoimmune indications.
Use of Interest
| Reporting Date | Total Revenue | Total Operating Expense | Interest Income | Interest Expense | Interest Income Ratio | Interest Expense Ratio |
|---|
Company Impact
Help us evaluate Sonnet BioTherapeutics Holdings Inc's impact from a halal perspective. Vote on the most significant aspect and submit any considerations that we may have missed.